UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

NPJ precision oncology, 2021-07, Vol.5 (1), p.69-69, Article 69

2021

Volltextzugriff (PDF)

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials

Annals of oncology, 2015-09, Vol.26 (9), p.1808-1812

2015

Volltextzugriff (PDF)

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence

Oral oncology, 2023-12, Vol.147, p.106587-106587, Article 106587

2023

Volltextzugriff (PDF)

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Annals of oncology, 2017-03, Vol.28 (3), p.590-596

2017

Volltextzugriff (PDF)

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

Investigational new drugs, 2020-04, Vol.38 (2), p.402-409

2020

Volltextzugriff (PDF)

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival

European journal of cancer (1990), 2018-03, Vol.91, p.47-55

2018

Volltextzugriff (PDF)

Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical oncology (Royal College of Radiologists (Great Britain)), 2022-12, Vol.34 (12), p.e473-e481

2022

Volltextzugriff (PDF)

Novel patterns of response under immunotherapy

Annals of oncology, 2019-03, Vol.30 (3), p.385-396

2019

Volltextzugriff (PDF)

Review of clinical applications of radiation-enhancing nanoparticles

Biotechnology reports (Amsterdam, Netherlands), 2020-12, Vol.28, p.e00548-e00548, Article e00548

2020

Volltextzugriff (PDF)

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Annals of oncology, 2017-07, Vol.28 (7), p.1605-1611

2017

Volltextzugriff (PDF)

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

Annals of oncology, 2020-03, Vol.31 (3), p.377-386

2020

Volltextzugriff (PDF)

CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database

Breast (Edinburgh), 2020-02, Vol.49, p.17-24

2020

Volltextzugriff (PDF)

Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

NPJ precision oncology, 2021-09, Vol.5 (1), p.86-86, Article 86

2021

Volltextzugriff (PDF)

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Annals of oncology, 2019-08, Vol.30 (8), p.1381-1392

2019

Volltextzugriff (PDF)

SP-035: Is there still a role for targeted signaling agents in head and neck cancer?

Radiotherapy and oncology, 2017-03, Vol.122, p.20-21

Le Tourneau, C

2017

Volltextzugriff (PDF)

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary

Annals of oncology, 2018-01, Vol.29 (1), p.30-35

2018

Volltextzugriff (PDF)

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Annals of oncology, 2018-09, Vol.29 (9), p.1911-1917

2018

Volltextzugriff (PDF)

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach

Annals of oncology, 2018-12, Vol.29 (12), p.2313-2327

2018

Volltextzugriff (PDF)

Designs of drug-combination phase I trials in oncology: a systematic review of the literature

Annals of oncology, 2015-04, Vol.26 (4), p.669-674

2015

Volltextzugriff (PDF)

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

British journal of cancer, 2008-10, Vol.99 (8), p.1197-1203

2008

Volltextzugriff (PDF)

Thérapeutiques moléculaires ciblées en oncologie ORL

Bulletin du cancer, 2010-12, Vol.97 (12), p.1453-1466

Le Tourneau, C.

2010

Volltextzugriff (PDF)

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

Annals of oncology, 2013-03, Vol.24 (3), p.761-769

2013

Volltextzugriff (PDF)

Characteristics Of Patients Treated With Cetuximab-Based Extreme Regimen In 1ST Line R/M Scchn Cancer In Real Life Setting, In France In 2012-2015

Value in health, 2017-10, Vol.20 (9), p.A462

2017

Volltextzugriff (PDF)

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells

British journal of cancer, 2007-08, Vol.97 (5), p.628-636

2007

Volltextzugriff (PDF)

Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets

European journal of cancer (1990), 2019-11, Vol.121, p.202-209

2019

Volltextzugriff (PDF)

1 – 25 von 914

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(754)
Mit Volltextzugriff
(795)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Annals Of Oncology
(143)
Ius Canonicum
(55)
Archives Of Cardiovascular Diseases Supplements
(34)
Annales De Pathologie
(23)
Arabica
(23)
Archives Of Cardiovascular Diseases. Supplements
(22)
Revue Historique
(17)
Bulletin Du Cancer
(16)
European Heart Journal
(16)
European Journal Of Cancer
(16)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence

Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma

Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival

Efficacy and Tolerance of Carboplatin plus Cetuximab (Simplified EXTREME Regimen) in Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma

Novel patterns of response under immunotherapy

Review of clinical applications of radiation-enhancing nanoparticles

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer

CinéBreast-factors influencing the time to first metastatic recurrence in breast cancer: Analysis of real-life data from the French ESME MBC database

Author Correction: Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

SP-035: Is there still a role for targeted signaling agents in head and neck cancer?

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary

First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer

Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach

Designs of drug-combination phase I trials in oncology: a systematic review of the literature

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

Thérapeutiques moléculaires ciblées en oncologie ORL

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

Characteristics Of Patients Treated With Cetuximab-Based Extreme Regimen In 1ST Line R/M Scchn Cancer In Real Life Setting, In France In 2012-2015

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells

Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets

Suchergebnisse filtern